Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Sponsors
Investigator Initiated Trial
ISMPO Indian Society of Medical and Paediatric Oncology
Eligibility
Inclusion criteria
Inclusion criteria: 1. Histologically confirmed high-risk endometrial cancer 2. FIGO stage IB grade 3 and above 3. Stage II III endometrioid carcinoma 4. Any stage serous or clear-cell carcinoma 5. Completion of primary surgery and adjuvant therapy 6. Availability of FFPE tissue
Exclusion criteria
Exclusion criteria: 1. Low-risk endometrial cancer or missing critical clinical/tissue data 2. Recurrent/metastatic disease at initial presentation 3. Lost to follow-up within six months post-treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assess the impact of molecular classification (POLEmut, MMRd, p53abn, NSMP) on clinical outcomes, including progression-free survival (PFS) and overall survival (OS), in Indian patients with high-risk endometrial cancer.Timepoint: 24 Months (2 Year) | — |
Secondary
| Measure | Time frame |
|---|---|
| - To describe the distribution of molecular subtypes in high-risk EC patients in India. - To correlate molecular classification with clinicopathologic variables such as age, stage, histology, and lymphovascular space invasion (LVSI). - To assess patterns of recurrence (local vs. distant) by molecular subgroup.Timepoint: 24 Months (2 Year) | — |
Countries
India
Contacts
Public ContactDr Anbarasan Sekar
Advanced Centre for Treatment, Research and Education in Cancer
Outcome results
None listed